Oxurion N.V. (TBGNF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Oxurion N.V. (TBGNF) trades at $0.17. Oxurion NV is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases. Market cap: $434M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for TBGNF: TBGNF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TBGNF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on TBGNF.
How is this calculated? →Oxurion N.V. (TBGNF) Healthcare & Pipeline Overview
Oxurion NV, a Belgian biopharmaceutical company, specializes in developing and commercializing innovative therapies for eye diseases, including its lead product JETREA for vitreomacular adhesion/traction, and novel treatments for diabetic macular edema, positioning it within a competitive ophthalmology market with unmet needs.
What Is the Investment Thesis for TBGNF?
Oxurion NV presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on ophthalmology, particularly its pipeline of Phase II clinical trials for THR-149 and THR-687 targeting diabetic macular edema (DME), represents a potential growth catalyst. Successful clinical trial outcomes and subsequent regulatory approvals could drive significant value. However, the company's negative gross margin of -4050.0% and reliance on clinical trial success pose substantial risks. The company's market capitalization is $0.43 billion, and its P/E ratio is 0.03. Investors should carefully weigh the potential for pipeline success against the inherent risks of biotechnology investments and the company's financial performance.
Based on FMP financials and quantitative analysis
TBGNF Key Highlights
Market capitalization of $434M reflects the company's current valuation in the biotechnology market.
- A P/E ratio of 0.03, which may not be meaningful due to the company's earnings situation.
- Profit Margin of 97950.0% indicates potential profitability if products are commercialized successfully.
- Gross margin of -4050.0% highlights the challenges in cost management and revenue generation.
- Beta of 0.35 suggests lower volatility compared to the overall market, but this may not reflect the inherent risks of biotechnology.
Who Are TBGNF's Competitors?
TBGNF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CCHWF Columbia Care Inc. | $0.94 | -21.71% | $521M | 41 |
| CKDXF Opthea Limited | $0.01 | +0.00% | $13.7M | 53 |
| CSSPF NIOX Group Plc | $0.82 | +0.00% | $345M | 47 |
| DFHL Dong Fang Hui Le Inc. | $4.00 | -11.11% | $400M | 44 |
| IVEVF Inventiva S.A. | $3.59 | +0.00% | $848M | 55 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| MDXG MiMedx Group, Inc. | $4.45 | +2.53% | $649M | 90 |
| CRMD CorMedix Inc. | $8.33 | -2.19% | $654M | 95 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TBGNF's Key Strengths?
Proprietary drug formulations for eye diseases.
- Pipeline of Phase II clinical trials for DME treatments.
- Collaboration agreements with established biotechnology companies.
- Established product in JETREA for vitreomacular adhesion/traction.
What Are TBGNF's Weaknesses?
Negative gross margin.
- Reliance on clinical trial success.
- Limited commercialized product portfolio.
- Small number of employees.
What Could Drive TBGNF Stock Higher?
TBGNF catalyst: Results from Phase II clinical trials for THR-149 in diabetic macular edema (DME) are expected in [Date Unknown], which could drive positive investor sentiment if successful.
- Results from Phase II clinical trials for THR-687 in diabetic macular edema (DME) are expected in [Date Unknown], potentially validating the integrin antagonist approach.
- Commercialization efforts for JETREA continue to generate revenue, although the impact is limited by market competition and product lifecycle.
- Strategic collaborations with Bicycle Therapeutics, INC Research, and Galapagos NV may yield new drug candidates or development opportunities.
- Potential for new partnerships or licensing agreements to expand the pipeline or geographic reach in [Date Unknown].
What Are the Key Risks for TBGNF?
Financial-distress signal — its Altman Z-Score of -23.12 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for THR-149 or THR-687 could significantly impact the company's valuation and future prospects.
- Competition from established pharmaceutical companies with larger resources and broader product portfolios poses a threat to Oxurion's market share.
- Regulatory hurdles and delays in obtaining marketing approvals for new drugs could delay commercialization and reduce revenue potential.
- The company's negative gross margin and reliance on external funding sources create financial risks.
- Patent expirations and generic competition for JETREA could erode revenue streams.
What Are the Growth Opportunities for TBGNF?
- Expansion of THR-149 for DME Treatment: THR-149, a plasma kallikrein inhibitor in Phase II clinical trials, represents a significant growth opportunity for Oxurion. Positive clinical trial results and subsequent regulatory approval could establish THR-149 as a key player in the DME treatment landscape, providing substantial revenue growth for Oxurion.
- Advancement of THR-687 for DME: THR-687, an integrin antagonist also in Phase II clinical trials for DME, offers another potential growth avenue. The drug's novel mechanism of action could address unmet needs in DME treatment, potentially capturing a significant share of the market. Success in clinical trials and regulatory approval are critical milestones for realizing this growth opportunity. The timeline for commercialization depends on the progress of clinical trials.
- Geographic Expansion of JETREA: While JETREA is already commercialized, expanding its geographic reach could provide additional revenue streams. Targeting emerging markets with growing healthcare infrastructure and increasing awareness of vitreomacular adhesion/traction could unlock new growth opportunities. This expansion would require strategic partnerships and investment in marketing and distribution channels. The timeline for geographic expansion depends on regulatory approvals and market access strategies.
- Strategic Partnerships and Collaborations: Oxurion's existing collaborations with Bicycle Therapeutics, INC Research, and Galapagos NV highlight the importance of partnerships in the biotechnology industry. Forming new strategic alliances with pharmaceutical companies or research institutions could accelerate the development and commercialization of its pipeline products. These partnerships could provide access to funding, expertise, and distribution networks, enhancing Oxurion's growth prospects. The timing and nature of these partnerships are uncertain.
- Acquisition or Licensing of New Assets: Oxurion could pursue growth through the acquisition or licensing of new assets in the ophthalmology space. This could involve acquiring rights to promising drug candidates or technologies that complement its existing pipeline. Such acquisitions could expand Oxurion's product portfolio and diversify its revenue streams. The availability of suitable assets and the company's financial resources will determine the feasibility of this growth strategy.
What Are TBGNF's Competitive Advantages?
- Proprietary drug formulations for eye diseases.
- Patent protection for key pipeline products.
- Clinical trial data supporting the efficacy and safety of its drugs.
- Established relationships with key opinion leaders in ophthalmology.
What Does TBGNF Do?
Founded in 1991 and headquartered in Leuven, Belgium, Oxurion NV, formerly known as ThromboGenics NV, is a biopharmaceutical company dedicated to developing and commercializing innovative medicines for the treatment of eye diseases. The company's lead product, JETREA, is designed to address vitreomacular adhesion/vitreomacular traction, a condition affecting the vitreous humor and retina. In addition to JETREA, Oxurion is actively engaged in the development of THR-149, a plasma kallikrein inhibitor currently in Phase II clinical trials for the treatment of diabetic macular edema (DME). THR-687, an integrin antagonist, is also in Phase II clinical trials for DME. These pipeline products represent Oxurion's commitment to addressing significant unmet needs in the treatment of retinal diseases. Oxurion has established collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV to support its research and development efforts. The company's focus on ophthalmology and its pipeline of novel therapies position it as a player in the biotechnology sector.
What Products and Services Does TBGNF Offer?
- Develop and commercialize medicines for eye diseases.
- Focus on treatments for vitreomacular adhesion/traction.
- Develop plasma kallikrein inhibitors for diabetic macular edema (DME).
- Develop integrin antagonists for DME.
- Conduct Phase II clinical trials for THR-149 and THR-687.
- Collaborate with other biotechnology and research companies.
How Does TBGNF Make Money?
- Develops pharmaceutical products for eye diseases.
- Generates revenue through the sale of JETREA.
- Out-licenses or partners for development and commercialization of other pipeline products.
- Secures funding through venture capital and public offerings.
What Industry Does TBGNF Operate In?
Oxurion NV operates within the biotechnology industry, specifically targeting the ophthalmology market. This market is characterized by increasing prevalence of eye diseases such as diabetic macular edema (DME) and age-related macular degeneration (AMD), driving demand for innovative therapies. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms, all vying for market share. Oxurion's focus on novel treatments for DME and its existing product, JETREA, position it to capitalize on the growing demand for effective eye disease therapies.
Who Are TBGNF's Key Customers?
- Patients with vitreomacular adhesion/traction.
- Patients with diabetic macular edema (DME).
- Ophthalmologists and retinal specialists.
- Hospitals and clinics.
How Oxurion N.V. Is Valued
Oxurion N.V. carries a market capitalization of $434M, placing it in the small-cap category.
Company Profile
Oxurion N.V. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Leuven, BE. The company is led by CEO Thomas Graney. TBGNF has traded publicly since 2007.
Key Financial Metrics
Return on equity for Oxurion N.V. stands at 30.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -97.5%, showing how much profit it generates from its asset base. A current ratio of 0.11 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Oxurion N.V.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -23.12 places it in the distress zone, a signal of elevated financial risk.
TBGNF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Oxurion's potential, indicating that executives believe in the company's future growth.
- Community sentiment has shifted positively as discussions around new drug developments have gained traction, highlighting investor enthusiasm.
- The company’s recent advancements in retinal therapies have sparked interest, positioning Oxurion as a key player in a growing market.
- Increased engagement on social media platforms reflects a growing base of retail investors rallying around Oxurion's innovative approaches.
Bear Case
- Concerns remain regarding the company's financial stability, with some investors questioning the sustainability of its funding sources.
- Recent clinical trial results have faced skepticism, leading to doubts about the efficacy of their treatments among the investor community.
- Negative sentiment has emerged from discussions around competition in the biotech space, with some believing Oxurion may struggle to differentiate itself.
- Overall market volatility has created a cautious atmosphere, leading some investors to adopt a bearish stance on smaller biotech firms like Oxurion.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TBGNF Latest News
No recent news available for TBGNF.
TBGNF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TBGNF.
Price Targets
Wall Street price target analysis for TBGNF.
TBGNF MoonshotScore
What does this score mean?
The MoonshotScore rates TBGNF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Thomas Graney
CEO
Thomas Graney serves as the CEO of Oxurion NV. His background includes experience in the pharmaceutical and biotechnology industries, with a focus on strategic leadership and business development. He is responsible for overseeing the company's operations, driving its strategic direction, and managing its research and development programs. His expertise is crucial for guiding Oxurion through the clinical trial process and commercializing its products.
Track Record: Under Thomas Graney's leadership, Oxurion NV has focused on advancing its pipeline of novel therapies for eye diseases, particularly diabetic macular edema (DME). He has overseen the progression of THR-149 and THR-687 through Phase II clinical trials. His strategic decisions have aimed to position Oxurion as a player in the ophthalmology market.
TBGNF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Oxurion N.V. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and requires increased due diligence from investors compared to exchange-listed stocks.
- OTC Tier: OTC Other
- Limited financial disclosure may make it difficult to assess the company's financial health.
- Lower trading volumes can lead to price volatility and difficulty in executing trades.
- OTC stocks are subject to less regulatory oversight than exchange-listed stocks.
- The OTC Other tier is associated with higher risk of fraud or manipulation.
- Delisting from the OTC market is a potential risk.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volumes and price volatility.
- Consult with a financial advisor before investing.
- Confirm the company's registration status with regulatory authorities.
- The company has been in operation since 1991.
- Oxurion NV has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV.
- The company has products in Phase II clinical trials.
- The company was formerly listed under the name ThromboGenics NV.
- The company has a CEO, Thomas Graney.
Oxurion N.V. Healthcare Stock: Key Questions Answered
What does Oxurion N.V. do?
Oxurion N.V. is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of eye diseases. Its lead product, JETREA, is used for the treatment of vitreomacular adhesion/traction. The company is also developing THR-149, a plasma kallikrein inhibitor, and THR-687, an integrin antagonist, both in Phase II clinical trials for the treatment of diabetic macular edema (DME).
What do analysts say about TBGNF stock?
Analyst opinions on TBGNF stock are currently unavailable. Key valuation metrics to consider include the company's market capitalization, P/E ratio, and gross margin. Growth considerations center around the success of its Phase II clinical trials for THR-149 and THR-687, as well as the commercial performance of JETREA. Investors should conduct their own due diligence and consider the risks associated with biotechnology investments.
What are the main risks for TBGNF?
The main risks for TBGNF include the potential failure of its Phase II clinical trials for THR-149 and THR-687, which could significantly impact the company's valuation. Competition from larger pharmaceutical companies with established products in the ophthalmology market also poses a threat. Regulatory hurdles and delays in obtaining marketing approvals for new drugs could delay commercialization.
What are the key factors to evaluate for TBGNF?
Evaluate TBGNF on fundamentals, analyst consensus, and risk factors. Oxurion NV presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does TBGNF data refresh on this page?
TBGNF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TBGNF's recent stock price performance?
Oxurion N.V. (TBGNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary drug formulations for eye diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TBGNF overvalued or undervalued right now?
Oxurion N.V. (TBGNF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TBGNF before investing?
Before investing in Oxurion N.V. (TBGNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be outdated or incomplete.
- Analyst opinions are not currently available.
- Clinical trial outcomes are uncertain.